Investor Presentaiton
Key Business Performance
TruximaⓇ
In Europe, the market share has decreased during the transition to go direct in 1H22, expected to be
recovered gradually with the start of direct sales in 2H22
✓ Despite pricing pressure amid intensified competition, maintaining stable market share in the US
M/S of TruximaⓇ in Europe
M/S of TruximaⓇ in the US
18%
39%
40%
35% 38%
37%
36%
31%
Volume
20.1Q 2Q 3Q
4Q 21.1Q
2Q
3Q 4Q 22.1Q
2Q
3Q
TruximaⓇ
D Biosimilar
Value
29%
24%
17.4Q
18.2Q
4Q 19.2Q
4Q
20.2Q 4Q 21.2Q
4Q
22.2Q
20.1Q 2Q
3Q
4Q 21.1Q 2Q
3Q
4Q
22.1Q
2Q
3Q
MabtheraⓇ
Truxima a®
C Biosimilar
TruximaⓇ
D Biosimilar
Note: The market share is based on volume
Source: IQVIA
Source Symphony Health
Investor Relations 2022 11
37%
28%
32%
28%View entire presentation